Letter to the Editor: Stem Cell Politics
By Richard Hayes,
New York Times
| 05. 01. 2006
To the Editor:
Re "Democrats Hope to Divide G.O.P. Over Stem Cells" (news article, April 24):
I'm a lifelong Democrat, pro-choice on abortion and in favor of stem cell research. But over-the-top promotion of this research is a mistake that could come back to bite us, and its use as a wedge issue is ill advised.
Stem cells may still prove to be a therapeutic dry hole. If successfully developed, stem cell therapies are likely to be prohibitively expensive.
Stem cell research puts women who donate eggs at significant medical risk, and could foster trafficking in eggs from poor women in developing countries.
The same stem cell technologies that might have beneficial medical applications could be used by rogue scientists intent on creating human clones and genetically modified children.
Stem cell research should be allowed, but it should proceed cautiously, under tight federal oversight.
Richard Hayes
Executive Director
Center for Genetics and Society
Oakland, Calif., April 24, 2006
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...